##  [Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia](/us-en/news/media-releases/novartis-drug-exjade-first-treatment-approved-fda-chronic-iron-overload-patients-non-transfusion-dependent-thalassemia-0 "Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia") 

  Jan 23, 2013